Proliferation: the most prominent predictor of clinical outcome in breast cancer.
about
Modulation of Runx2 activity by estrogen receptor-alpha: implications for osteoporosis and breast cancerProliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markersBreast tumors with elevated expression of 1q candidate genes confer poor clinical outcome and sensitivity to Ras/PI3K inhibitionRespective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinomaPrognostic value of gene signatures and proliferation in lymph-node-negative breast cancerCell cycle correlated genes dictate the prognostic power of breast cancer gene lists.Intrinsic bias in breast cancer gene expression data sets.A systems biology-based gene expression classifier of glioblastoma predicts survival with solid tumors.Improved microarray-based decision support with graph encoded interactome dataTailoring to RB: tumour suppressor status and therapeutic response.The history and future of targeting cyclin-dependent kinases in cancer therapy.Challenges in Biomarker Discovery: Combining Expert Insights with Statistical Analysis of Complex Omics Data.Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation.International Agency for Research on Cancer workshop on 'Expression array analyses in breast cancer taxonomy'Phospho-TCTP as a therapeutic target of Dihydroartemisinin for aggressive breast cancer cells.Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome.Stromal genes add prognostic information to proliferation and histoclinical markers: a basis for the next generation of breast cancer gene signatures.Re-evaluating early breast neoplasia.Proliferation marker securin identifies favourable outcome in invasive ductal breast cancer.Transcriptomic signatures in breast cancer.Distant metastasis: not out of reach any moreMicroarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?Preinvasive breast cancer.Systematically defining single-gene determinants of response to neoadjuvant chemotherapy reveals specific biomarkers.The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade.Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer.Clinical usefulness of AJCC response criteria for neoadjuvant chemotherapy in breast cancer.The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity.The ubiquitin-conjugating enzyme E2-EPF is overexpressed in primary breast cancer and modulates sensitivity to topoisomerase II inhibition.Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients.[Genome-wide expression profiling as a clinical tool: are we there yet?].Molecular Subtypes and Local-Regional Control of Breast Cancer.Low cdc27 and high securin expression predict short survival for breast cancer patients.Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?ESPL1 is a candidate oncogene of luminal B breast cancers.
P2860
Q24654971-6E6E8605-2DBE-402D-9A9C-ED577A64D02CQ28289007-1FEDDA9E-17C2-4619-BB89-1E3B92769FB8Q28534478-D09FEFD6-1AAE-4C6D-B8F6-EF211CC7EE7BQ28730529-8CDE995F-688B-41D7-80EC-AE075BBCC8F7Q31152670-9644847B-E440-4345-B496-1E5414474F0BQ33331012-6F17900F-EABD-44D6-8A0A-053CBB842083Q33475987-D6939FC5-B330-4517-B322-3896D79A49AFQ33483366-A6337DF3-8DA8-46CD-A8D1-B753C7691418Q33564252-935DE4EB-4FEA-45EB-8637-5D3F10671C92Q34040108-33AF059A-B91E-47AB-AF10-41AD87BEE2CCQ34460347-5143CF23-230F-473E-9540-EF23E146D873Q34555631-62A7FE50-3937-489D-81FA-7575E4E5EE89Q35034575-BB12A58C-3421-4EF4-8230-0F92B97047FDQ35156922-95D5FCC9-E402-4178-A1E8-F6306F0929CAQ35633717-58794013-1900-40C2-82E2-AFB780727463Q35741661-F9DABACF-0710-4C3C-8A1F-09360275C02DQ35906318-337034E1-05E9-462C-9657-350BF6F0F821Q36040493-E3C9C38A-4372-439F-B51B-75CED4007364Q36643056-A884D539-28BC-4614-95E9-6369D5245745Q36785943-5E40BA6A-8BEA-425B-B74B-A1D64524D7E8Q36853657-11B6546C-075F-493E-939A-75069F8D63BFQ37209976-2A057CF6-DA91-4C80-A01B-CE8D4A184D67Q37356684-76AD4601-0B2F-4FC0-B35E-D82E4F49B5CEQ37569919-C31EA5CB-F688-4CAC-8608-8B886271C5CAQ37618855-831D3065-3609-4231-97C2-3CA608A88FA1Q37635788-9AEE0670-AE75-48BE-91A7-089DA769E1AEQ37688324-14BD272A-809E-4C20-913D-45EC1CF9221BQ38451966-EBFE0DCC-F7A2-4A63-9F6F-33861820C175Q39183079-92A30BB2-EB51-4276-A806-F2AA54BA535DQ39859811-904E78EE-D1BC-4350-9253-49CA63800D42Q42128025-5514043F-ABF6-4FD6-BA6E-0BE573956FF9Q43632403-E3768E85-C2C4-4EA6-A0B5-8D2434551CABQ46083625-FE18341D-2FCF-49CA-8E56-FCC8FC56B33FQ48674329-5B48A23C-C169-4AB9-A6B1-D7EF0B5560EBQ50045468-E56DE140-3D25-4A8A-A014-EDE865F8EA5EQ50918197-5F894230-51B6-462C-8393-6259545D0634Q51912002-D80A3421-FE29-41F9-970A-EFE3B3AF9158Q54196117-90A6B19F-A228-4502-A47F-7255790ABE10
P2860
Proliferation: the most prominent predictor of clinical outcome in breast cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Proliferation: the most prominent predictor of clinical outcome in breast cancer.
@ast
Proliferation: the most prominent predictor of clinical outcome in breast cancer.
@en
type
label
Proliferation: the most prominent predictor of clinical outcome in breast cancer.
@ast
Proliferation: the most prominent predictor of clinical outcome in breast cancer.
@en
prefLabel
Proliferation: the most prominent predictor of clinical outcome in breast cancer.
@ast
Proliferation: the most prominent predictor of clinical outcome in breast cancer.
@en
P356
P1433
P1476
Proliferation: the most prominent predictor of clinical outcome in breast cancer.
@en
P2093
Christine Desmedt
Christos Sotiriou
P304
P356
10.4161/CC.5.19.3254
P577
2006-10-01T00:00:00Z